Haleon plc (LON:HLN - Get Free Report) shares rose 1% during mid-day trading on Wednesday . The company traded as high as GBX 360.60 ($4.85) and last traded at GBX 358.50 ($4.82). Approximately 21,763,486 shares traded hands during mid-day trading, a decline of 15% from the average daily volume of 25,575,971 shares. The stock had previously closed at GBX 355 ($4.77).
Haleon Stock Performance
The company has a current ratio of 0.84, a quick ratio of 0.93 and a debt-to-equity ratio of 53.36. The stock has a fifty day moving average price of GBX 386.17 and a 200-day moving average price of GBX 385.40. The firm has a market capitalization of £33.02 billion, a price-to-earnings ratio of 30.77, a PEG ratio of 1.49 and a beta of 0.19.
Insider Buying and Selling
In other Haleon news, insider Marie-Anne Aymerich purchased 21,300 shares of the firm's stock in a transaction that occurred on Friday, May 9th. The shares were acquired at an average cost of GBX 405 ($5.44) per share, for a total transaction of £86,265 ($115,932.00). Also, insider Dawn Allen sold 64,329 shares of the stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of GBX 376 ($5.05), for a total value of £241,877.04 ($325,059.86). In the last quarter, insiders acquired 42,869 shares of company stock valued at $17,294,104. 10.74% of the stock is currently owned by corporate insiders.
Haleon Company Profile
(
Get Free Report)
Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.
See Also
Before you consider Haleon, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.
While Haleon currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
